Loading
ROS1 Gene Rearrangement / Brain Metastases / Repotrectinib · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registry entry for an ongoing Phase 2 study of repotrectinib in ROS1-positive NSCLC patients with active brain metastases. No results have been posted in this registry record. The study is actively recruiting with planned enrollment of 20 participants and expected average follow-up of 13 months.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. NSCLC, Brain Metastases, ROS1 Gene Rearrangement; age from 18 Years. Intervention: Repotrectinib. n = 20. 17 sites: Austria, Germany, Spain.
This is a clinical trial registry entry for an ongoing Phase 2 study of repotrectinib in ROS1-positive NSCLC patients with active brain metastases. No results have been posted in this registry record. The study is actively recruiting with planned enrollment of 20 participants and expected average follow-up of 13 months.
This is a registry record only; no efficacy, safety, or outcome data are reported.
The source did not state who this applies to in practice.
This is a recruiting Phase 2 trial with no results posted; it describes a planned study of repotrectinib in a specific population but carries no efficacy or safety data yet.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06315010). This is a study registration, not published results. Lead sponsor: MedSIR. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: NSCLC, Brain Metastases, ROS1 Gene Rearrangement. Interventions: DRUG: Repotrectinib. Primary outcome measures: Intracranial Objective Response Rate (IC-ORR) , From date of inclusion until the date of first documented progression or date of death from any cause or treatment discontinuation from any other reason, whichever came first, assessed through study completion, an average of 13 months.. Brief summary: REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.